Amyloidosis relapsing after autologous stem cell transplantation treated with Bortezomib: normalization of detectable serum-free light chains and reversal of tissue damage with improved suitability for transplant Systemic amyloidosis (AL) is a plasma cell dyscrasia in which the clone secretes free κ-or λ-immunoglobulin light chains (FLCs).
1 These light chains do not fold into the proper tertiary conformation and form protein deposits, causing organ damage. 2 The most commonly affected organs are the heart, liver, kidney, gut, and peripheral nerves.
3 Standard treatment for patients with good performance status includes high-dose melphalan with autologous stem cell transplantation (ASCT).
1,4
Patients with organ dysfunction have increased transplant-related mortality. 5, 6 Medications that treat AL without increasing the mortality of definitive treatment, currently ASCT, are sought. Bortezomib is a proteasome inhibitor that is effective in the treatment of plasma cell dyscrasias. 7 We utilized bortezomib to treat two patients with recurrent AL after initial ASCT. Both patients provided written informed consent according to the Helsinki Convention for their initial treatment, for ASCT, for bortezomib treatment of their relapsed disease, and for anonymous data collection. ASCT provides a substantial median survival in select AL patients, 8 but has a >25% mortality rate if even one organ has significant AL damage. 8, 9 Our data suggest treatments that improve end-organ damage should reduce transplant-related mortality, ultimately allowing a higher percentage of patients to undergo ASCT with improved outcomes.
10 Bortezomib can reliably decrease serum FLC levels.
11 In our two patients we documented reversal of AL organ damage with what appears to be promising disease-free survival. Furthermore, patient 1, who received a second transplant, has remained in remission for 3 years. This suggests that second transplants may result in improved outcomes by significantly decreasing the AL disease burden. Treatment with bortezomib-based therapy may result in hematologic and organ responses that would enable patients with endorgan damage who would have otherwise been precluded from transplantation to undergo ASCT. 
